T-Cure -Model 800TCR -Human Endogenous Retro-Virus (HERV)

The HERV-E target is one of the quiescent Human Endogenous Retro-Virus (HERV) sequences that are turned on during tumor development. Its expression in renal cell carcinoma (RCC) is highly selective, with no transcripts detected in any normal tissues. It is expressed in 85% of clear cell RCC (ccRCC). The TCR molecule was identified in a responding patient, following allogeneic stem cell therapy. Currently there is an ongoing investigator-initiated trial at the NIH for metastatic ccRCC patients with progressive disease following anti-angiogenic drug and nivolumab (anti-PD1) therapy (NCT03354390). T-Cure has licensed the HERV-E targeted TCR from the NIH and has an active CRADA collaboration with the NIH to develop HERV-E TCRs in solid tumors.